Open an account

Merck KGaA

MKGAF · XETRA

$167.21+$9.24 (+5.85%)TodayMarket closed ·
Prev close $157.97

About MKGAF

Merck KGaA is a science and technology company, which engages in the manufacture of pharmaceutical and chemical products. The company is headquartered in Darmstadt, Hessen and currently employs 62,461 full-time employees. The firm operates in three business segments: Healthcare, Life Sciences and Electronics. The Healthcare business segment is operating in the therapeutic areas of oncology, neurology & immunology and fertility as well as cardiovascular, metabolic and endocrinological disorders. The Life Sciences segment is operating with its three business units such as, Science & Lab Solutions, Process Solutions and Life Science Services. The company is also a supplier of products, tools and services for research laboratories, pharmaceutical and biopharmaceutical production as well as industrial and testing laboratories. The Electronics business segment consists of the Semiconductor Solutions, Display Solutions and Surface Solutions business units. Its Semiconductor Solutions business unit consists of the thin films, formulations, specialty gases, and delivery systems & services business fields.

Employees
59,077
Headquarters
Darmstadt, Hessen
Listed
Oct 20, 1995
Sector
Health Care
Industry
Pharmaceuticals
Website
merckgroup.com

MKGAF key statistics

Market cap
62.76B
Price-earnings ratio
0.00
Dividend yield
0.45%
Average volume
739
Volume
350
Open price
$167.14
High today
$169.04
Low today
$167.14
52 Week high
$175.56
52 Week low
$116.68

Merck KGaA (MKGAF) at a glance

As of Oct 20, 2026, Merck KGaA (MKGAF) shares are priced at $167.21, giving the company a market cap of 62.76B, a price-to-earnings ratio of 0.00 and a dividend yield of 0.45%.

Today the stock has traded between $167.14 and $169.04. The current price is 0.0% above the day's low and 1.1% below its high.

Volume so far is 350 shares, below the average of 739 shares a day.

Over the past year Merck KGaA has ranged from $116.68 to $175.56, and now sits 86% of the way up that range.

Merck KGaA met or beat analyst EPS estimates in 3 of the last 8 quarters. In Q2 FY26 it reported $2.16 per share against an estimate of $2.14.

MKGAF earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 8 quarters, by 4.4% on average.

  1. Q3 FY24: reported $2.30 per share against an estimate of $2.31
  2. Q4 FY24: reported $2.07 per share against an estimate of $2.12
  3. Q1 FY25: reported $2.12 per share against an estimate of $2.20
  4. Q2 FY25: reported $2.02 per share against an estimate of $2.12
  5. Q3 FY25: reported $2.32 per share against an estimate of $2.24
  6. Q4 FY25: reported $1.88 per share against an estimate of $1.95
  7. Q1 FY26: reported $2.11 per share against an estimate of $1.94
  8. Q2 FY26: reported $2.16 per share against an estimate of $2.14

MKGAF news

  • Vandana Singh

    Why Is Silence Therapeutics Stock Skyrocketing Monday?

  • Vandana Singh

    Werewolf Therapeutics Takes Aim At Untapped Pain Market With Ambros Deal

  • Vandana Singh

    Qiagen M&A Fever Builds: KKR, EQT, Advent Explore Possible Takeover

  • Vandana Singh

    Merck Germany Lands Bio-Techne In $11.3 Billion Cash Deal

  • Tanya Rawat

    Elizabeth Warren Calls Trump's '600%' Drug Price Claim Mathematically Impossible: 'His Promise Is As Empty As…'

  • Vandana Singh

    Large Drugmakers Eye Inhibrx Cancer Drugs Valued Over $8 Billion, Stock Surges

  • Vandana Singh

    White House Readies Drug Price Deals With AbbVie, Novartis, Roche

  • Evette Mitkov

    Invo Fertility Stock Is Plunging After White House Announcement

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.